Assessing Participation in Daily Living and the Effectiveness of Rehabiliation in Age Related Macular Degeneration Patients Using the Impact of Vision Impairment Scale

REFERENCES

• Gehrs K M, Anderson D H, Johnson L V, Hageman G S. Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann Med. 2006; 38: 450–71
   PubMed Web of Science ®Google Scholar
• O'Shea J G. Age-related macular degeneration: A leading cause of blindness. Med J Aust. 1996; 165: 561–4
   Web of Science ®Google Scholar
• Hassell J B, Lamoureux E L, Keeffe J E. Impact of age related macular degeneration on quality of life. Br J Ophthalmol. 2006; 90: 593–6
   PubMed Web of Science ®Google Scholar
• Williams R A, Brody B L, Thomas R G, Kaplan R M, Brown S I. The psychosocial impact of macular degeneration. Arch Ophthalmol. 1998; 116: 514–20
   PubMed Web of Science ®Google Scholar
• Mitchell J, Bradley P, Anderson S J, Ffytche T, Bradley C. Perceived quality of health care in macular disease: a survey of members of the Macular Disease Society. Br J Ophthalmol. 2002; 86: 777–81
   PubMed Web of Science ®Google Scholar
• Rovner B W, Casten R J, Tasman W S. Effect of depression on vision function in age-related macular degeneration. Arch Ophthalmol. 2002; 120: 1041–4
   PubMed Web of Science ®Google Scholar
• Frost N A, Sparrow J M, Durant J S, Donovan J L, Peters T J, Brookes S T. Development of a questionnaire for measurement of vision-related quality of life. Ophthalmic Epidemiol. 1998; 5: 185–210
   PubMedGoogle Scholar
• Steinberg E P, Tielsch J M, Schein O D, Javitt J C, Sharkey P, Cassard S D, Legro M W, Diener-West M, Bass E B, Damiano A M, et al. The VF–14. An index of functional impairment in patients with cataract. Arch Ophthalmol. 1994; 112: 630–8
   PubMed Web of Science ®Google Scholar
• Mangione C M, Lee P P, Gutierrez P R, Spritzer K, Berry S, Hays R D. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001; 119: 1050–8
   PubMed Web of Science ®Google Scholar
• Hart P M, Chakravarthy U, Stevenson M R, Jamison J Q. A vision specific functional index for use in patients with age related macular degeneration. Br J Ophthalmol. 1999; 83: 1115–20
   PubMed Web of Science ®Google Scholar
• Mitchell J, Wolffsohn J S, Woodcock A, Anderson S J, McMillan C V, Ffytche T, Rubinstein M, Amoaku W, Bradley C. Psychometric evaluation of the MacDQoL individualised measure of the impact of macular degeneration on quality of life. Health Qual Life Outcomes 2005; 3: 25
   Google Scholar
• Norquist J M, Fitzpatrick R, Dawson J, Jenkinson C. Comparing alternative Rasch-based methods vs raw scores in measuring change in health. Med Care 2004; 42: I25–36
   PubMed Web of Science ®Google Scholar
• Garamendi E, Pesudovs K, Stevens M J, Elliott D B. The Refractive Status and Vision Profile: Evaluation of psychometric properties and comparison of Rasch and summated Likert-scaling. Vision Res. 2006; 46: 1375–1383
   PubMed Web of Science ®Google Scholar
• Pesudovs K. Patient-centred measurement in ophthalmology - A paradigm shift. BMC Ophthalmol 2006; 6: 25
   PubMedGoogle Scholar
• Pesudovs K, Garamendi E, Elliott D B. The Quality of Life Impact of Refractive Correction (QIRC) Questionnaire: Development and validation. Optom Vis Sci. 2004; 81: 769–777
   PubMed Web of Science ®Google Scholar
• Pesudovs K, Garamendi E, Keeves J P, Elliott D B. The Activities of Daily Vision Scale for cataract surgery outcomes: re-evaluating validity with Rasch analysis. Invest Ophthalmol Vis Sci. 2003; 44: 2892–2899
   PubMed Web of Science ®Google Scholar
• Lamoureux E, Pallant J, Pesudovs K, Hassell J, Keeffe J. The Impact of Vision Impairment Questionnaire: An evaluation of its measurement properties using Rasch analysis. Invest Ophthalmol Vis Sci. 2006; 47: 4732–4741
   PubMed Web of Science ®Google Scholar
• Lamoureux E L, Pallant J F, Pesudovs K, Rees G, Hassell J B, Keeffe J E. The effectiveness of low-vision rehabilitation on participation in daily living and quality of life. Invest Ophthalmol Vis Sci. 2007; 48: 1476–82
   PubMed Web of Science ®Google Scholar
• Lamoureux E, Hooper C, Lim L, Pallant J, Hunt N, Keeffe J, Guymer R. Impact of cataract surgery on quality of life in patients with early age-related macular degeneration. Optom Vis Sci 2007; 84: 683–688
   PubMed Web of Science ®Google Scholar
• Weih L M, Hassell J B, Keeffe J E. Assessment of the impact of vision impairment. Invest Ophthalmol Vis Sci. 2002; 43: 927–935
   PubMed Web of Science ®Google Scholar
• Lamoureux E L, Pallant J F, Pesudovs K, Rees G, Hassell J B, Keeffe J E. The impact of vision impairment questionnaire: An assessment of its domain structure using confirmatory factor analysis and Rasch analysis. Invest Ophthalmol Vis Sci. 2007; 48: 1001–6
   PubMed Web of Science ®Google Scholar
• Rasch G. Probabilistic Models for Some Intelligence and Attainment Tests. University of Chicago Press, Chicago 1960
   Google Scholar
• Andrich D, Lyne A, Sheridan B, Luo G. RUMM 2020. RUMM Laboratory, Perth 2003
   Google Scholar
• van Alphen A, Halfens R, Hasman A, Imbos T. Likert or Rasch? Nothing is more applicable than good theory. J Adv Nurs. 1994; 20: 196–201
   PubMed Web of Science ®Google Scholar
• Tennant A, McKenna S P, Hagell P. Application of Rasch analysis in the development and application of quality of life instruments. Value Health 2004; 7(Suppl 1)S22–6
   PubMed Web of Science ®Google Scholar
• Smith E V. Detecting and evaluation the impact of multidimensionality using item fit statistics and principal component analysis of residuals. J Appl Measure. 2002; 3: 205–231
   PubMedGoogle Scholar
• Linacre J. A User's Guide to Winsteps: Rasch-Model Computer Program. Mesa Press, Chicago 2002
   Google Scholar
• Hair J F, Black W C, Babin B J, Anderson R E, Tatham R L. Multivariate Data Analysis, Sixth ed. Prentice Hall, NJ 2005
   Google Scholar
• Byrne B. Structural equation modeling with AMOS: Basic concepts, applications, and programming. Lawrence Erlbaum Associates, New Jersey 2001
   Google Scholar
• Bentler P M. Comparative fit indexes in structural models. Psychol Bull. 1990; 107: 238–46
   PubMed Web of Science ®Google Scholar
• Kline R. Principles and practice of structural equation modeling, 2nd ed. Guilford Press, New York 2005
   Google Scholar
• Masters G. A Rasch model for partial credit scoring. Psychometrika. 1982; 47: 149–174
   Web of Science ®Google Scholar
• Lamoureux E, Ferraro J, Pallant J, Pesudovs K, Rees G, Keeffe J. Are standard instruments valid for the assessment of quality of life and symptoms in glaucoma. Optom Vis Sci. 2007; 84: 789–796
   PubMed Web of Science ®Google Scholar
• Tennant A, Pallant J. Unidimensionality matters (A tale of two Smiths?). Rasch Measurement Transactions 2006; 20: 1
   Google Scholar
• Rovner B W, Casten R J. Neuroticism predicts depression and disability in age-related macular degeneration. J Am Geriatr Soc. 2001; 49: 1097–100
   PubMed Web of Science ®Google Scholar
• McGwin G, Jr., Chapman V, Owsley C. Visual risk factors for driving difficulty among older drivers. Accid Anal Prev. 2000; 32: 735–44
   PubMed Web of Science ®Google Scholar
• Hassan S E, Lovie-Kitchin J E, Woods R L. Vision and mobility performance of subjects with age-related macular degeneration. Optom Vis Sci. 2002; 79: 697–707
   PubMed Web of Science ®Google Scholar
• Klein B E, Moss S E, Klein R, Lee K E, Cruickshanks K J. Associations of visual function with physical outcomes and limitations 5 years later in an older population:The Beaver DamEye Study. Ophthalmology. 2003; 110: 644–50
   PubMed Web of Science ®Google Scholar
• Gragoudas E S, Adamis A P, Cunningham E T, Jr., Feinsod M, Guyer D R. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351: 2805–16
   PubMed Web of Science ®Google Scholar
• Rosenfeld P J, Rich R M, Lalwani G A. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am. 2006; 19: 361–72
   PubMedGoogle Scholar
• Rosenfeld P J, Brown D M, Heier J S, Boyer D S, Kaiser P K, Chung C Y, Kim R Y. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355: 1419–31
   PubMed Web of Science ®Google Scholar
• Heier J S, Antoszyk A N, Pavan P R, Leff S R, Rosenfeld P J, Ciulla T A, Dreyer R F, Gentile R C, Sy J P, Hantsbarger G, Shams N. Ranibizumab for treatment of neovascular age-related macular degeneration: A phase I/II multicenter, controlled, multidose study. Ophthalmology 2006; 113: e1–4, 642
   Web of Science ®Google Scholar